Risk factor
Weak & very vulnerable to price shocks
Profitability factor
Greatly overvalued vs peers
About
Bukwang Pharmaceutical Co., Ltd., a South Korean-based enterprise, conducts pharmaceutical operations both domestically and across international markets. The company manufactures a diverse array of pharmaceutical formats, encompassing oral solids, injectables, liquid solutions, and topical preparations like external-use solutions and ointments. Its product portfolio spans key therapeutic domains such as hepatology, featuring treatments like Levovir and Legalon for liver conditions; products addressing diabetic complications, including Dexid and Thioctacid; central nervous system disorder medications like Lonasen, Ixel, and Orfil; and respiratory disease remedies such as Azeptin and Asima. In addition to its prescription drug offerings, Bukwang provides over-the-counter (OTC) products, personal care items like toothpastes, hair, and skin care goods, and various nutritional supplements. Its comprehensive lineup extends to numerous other therapeutic categories, covering antihistamines, gastrointestinal disorders, oncology, endocrine conditions (thyroid, diabetes, osteoporosis), obstetrics, urogenital health, cardiovascular care, dermatology, weight management, and pain relief. It also addresses a wide spectrum of common ailments, including respiratory symptoms (colds, coughs, asthma), inflammatory and pain conditions (rheumatoid arthritis, osteoarthritis, general pain), various skin issues (infections, irritations), digestive complaints, and nutritional needs, along with specialized remedies for conditions like varicose veins and lactation support. Furthermore, the company supplies quasi-drugs, medical devices, and health functional foods. Committed to innovation, Bukwang is deeply involved in developing new treatments. This includes an anti-diabetes compound in collaboration with Melior Pharmaceuticals, anti-cancer drugs with LSK BioPartners, and explorations into adult stem cell-based therapies. It also possesses a licensing agreement for a promising candidate drug targeting movement disorders in Parkinson's disease patients. Established in Seoul, South Korea, in 1960, Bukwang Pharmaceutical remains strategically headquartered there.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBITDA,